Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Keenova Therapeutics plcMNK · Entity 28960 | EVP & President, Spec Gen | April 02, 2019 | April 03, 2019 |
| Qnity Electronics, Inc.Q · Entity 928 | Chief Financial Officer | December 03, 2025 | December 05, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Keenova Therapeutics plc
Report date April 02, 2019 · Filed April 03, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 104,115 |
Reported balance
After 2019-04-02 transaction · row 1
1 source rowRow 1 · 2019-04-02 · Tax withholding · Disposed 2,533 · Balance 104,115 |
Qnity Electronics, Inc.
Report date December 03, 2025 · Filed December 05, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Options (Right to Buy) NQOsSEC Table II · derivative / convertible security · Conversion / exercise price $80.28 · Expires 2035-12-02 | Direct | 49,807 |
Reported balance
After 2025-12-03 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-12-03 · Grant · Acquired 49,807 · Balance 49,807 |
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
NUVASIVE INC
Report date September 01, 2023 · Filed September 05, 2023
Section 16 reporting ended · disclosed 2023-09-05. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, par value $0.001 per shareSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2023-09-01 transaction · row 1
1 source rowRow 1 · 2023-09-01 · Disposition to issuer · Disposed 11,081 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of February 8, 2023 (the "Merger Agreement"), by and among the Issuer, Globus Medical, Inc. ("Globus") and Zebra Merger Sub, Inc. ("Merger Sub"), Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Globus. At the effective time of the merger (the "Effective Time"), each share of the Issuer's common stock issued and outstanding immediately prior to the Effective Time (other than certain excluded shares) was cancelled and converted into the right to receive 0.75 shares of Class A common stock of Globus ("Globus Class A Common Stock"), par value $0.001 per share (the "Exchange Ratio" and such shares, the "Merger Consideration"), and cash in lieu of fractional shares. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2023-09-01 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-09-01 · Disposition to issuer · Disposed 13,411 · Balance 0 F2: Represented a contingent right to receive one share of the Issuer's common stock upon vesting. F3: Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit award was converted into a Globus restricted stock unit award, with the number of shares of Globus Class A Common Stock subject to such assumed award determined based on the Exchange Ratio. Each converted Globus restricted stock unit award is subject to the same terms and conditions (including service-based vesting conditions) as applied to the corresponding Issuer restricted stock unit award as of immediately prior to the Effective Time. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2023-09-01 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2023-09-01 · Disposition to issuer · Disposed 14,677 · Balance 0 F2: Represented a contingent right to receive one share of the Issuer's common stock upon vesting. F3: Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit award was converted into a Globus restricted stock unit award, with the number of shares of Globus Class A Common Stock subject to such assumed award determined based on the Exchange Ratio. Each converted Globus restricted stock unit award is subject to the same terms and conditions (including service-based vesting conditions) as applied to the corresponding Issuer restricted stock unit award as of immediately prior to the Effective Time. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2023-09-01 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2023-09-01 · Disposition to issuer · Disposed 37,498 · Balance 0 F2: Represented a contingent right to receive one share of the Issuer's common stock upon vesting. F3: Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit award was converted into a Globus restricted stock unit award, with the number of shares of Globus Class A Common Stock subject to such assumed award determined based on the Exchange Ratio. Each converted Globus restricted stock unit award is subject to the same terms and conditions (including service-based vesting conditions) as applied to the corresponding Issuer restricted stock unit award as of immediately prior to the Effective Time. |
| Performance Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2023-09-01 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2023-09-01 · Disposition to issuer · Disposed 13,411 · Balance 0 F2: Represented a contingent right to receive one share of the Issuer's common stock upon vesting. F4: Pursuant to the Merger Agreement, at the Effective Time, each performance restricted stock unit award was converted into a Globus restricted stock unit award, with the number of shares of Globus Class A Common Stock subject to such assumed award determined based on the Exchange Ratio and with applicable performance conditions deemed to be achieved at 100% of the target performance level. Each converted Globus restricted stock unit award is subject to the same terms and conditions (including service-based vesting conditions but excluding performance-based vesting conditions) as applied to the corresponding Issuer performance restricted stock unit award subject to such award as of immediately prior to the Effective Time |
| Performance Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2023-09-01 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2023-09-01 · Disposition to issuer · Disposed 14,677 · Balance 0 F2: Represented a contingent right to receive one share of the Issuer's common stock upon vesting. F4: Pursuant to the Merger Agreement, at the Effective Time, each performance restricted stock unit award was converted into a Globus restricted stock unit award, with the number of shares of Globus Class A Common Stock subject to such assumed award determined based on the Exchange Ratio and with applicable performance conditions deemed to be achieved at 100% of the target performance level. Each converted Globus restricted stock unit award is subject to the same terms and conditions (including service-based vesting conditions but excluding performance-based vesting conditions) as applied to the corresponding Issuer performance restricted stock unit award subject to such award as of immediately prior to the Effective Time |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Agreement and Plan of Merger, dated as of February 8, 2023 (the "Merger Agreement"), by and among the Issuer, Globus Medical, Inc. ("Globus") and Zebra Merger Sub, Inc. ("Merger Sub"), Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Globus. At the effective time of the merger (the "Effective Time"), each share of the Issuer's common stock issued and outstanding immediately prior to the Effective Time (other than certain excluded shares) was cancelled and converted into the right to receive 0.75 shares of Class A common stock of Globus ("Globus Class A Common Stock"), par value $0.001 per share (the "Exchange Ratio" and such shares, the "Merger Consideration"), and cash in lieu of fractional shares.
F2: Represented a contingent right to receive one share of the Issuer's common stock upon vesting.
F3: Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit award was converted into a Globus restricted stock unit award, with the number of shares of Globus Class A Common Stock subject to such assumed award determined based on the Exchange Ratio. Each converted Globus restricted stock unit award is subject to the same terms and conditions (including service-based vesting conditions) as applied to the corresponding Issuer restricted stock unit award as of immediately prior to the Effective Time.
F4: Pursuant to the Merger Agreement, at the Effective Time, each performance restricted stock unit award was converted into a Globus restricted stock unit award, with the number of shares of Globus Class A Common Stock subject to such assumed award determined based on the Exchange Ratio and with applicable performance conditions deemed to be achieved at 100% of the target performance level. Each converted Globus restricted stock unit award is subject to the same terms and conditions (including service-based vesting conditions but excluding performance-based vesting conditions) as applied to the corresponding Issuer performance restricted stock unit award subject to such award as of immediately prior to the Effective Time
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 03, 2025 Filed Dec 5, 2025 21:13 UTC | Qnity Electronics, Inc. Q · Entity 928 | GrantStock Options (Right to Buy) NQOs · Derivative | 49,807 | $0.00 Strike: $80.28 | $0.00 |
DisclosureSEC source: 0001628280-25-055669 · wk-form4_1764987218.xml · derivative · entry 1 Harbaugh Matthew K · CIK 0001578368 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 49,807 Underlying: Common Stock · 49,807 shares Expires 2035-12-02 Read SEC document |
| November 01, 2025 Filed Nov 4, 2025 19:26 UTC | Qnity Electronics, Inc. Q · Entity 928 | OtherCommon Stock | 9,291.5511 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-25-049142 · wk-form4_1762302359.xml · nonDerivative · entry 1 Harbaugh Matthew K · CIK 0001578368 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,291.5511 F1 · shares: On November 1, 2025, the Reporting Person received a dividend of one (1) share of Qnity Electronics, Inc. ("Qnity") common stock for every two (2) shares of DuPont de Nemours, Inc. ("DuPont") held by the Reporting Person, and the Reporting Person's equity awards denominated in DuPont common stock were adjusted, in part, into equity awards denominated in Qnity common stock, all as described in Qnity's information statement filed as Exhibit 99.1 to the Current Report on Form 8-K that was filed by Qnity with the Securities and Exchange Commission on October 15, 2025, in connection with the spin-off of Qnity from DuPont. This amount includes restricted stock units and dividend equivalent units. Read SEC document |
| September 01, 2023 Filed Sep 5, 2023 16:34 UTC | NUVASIVE INC NUVA · Entity 110002 | Disposition to issuerPerformance Restricted Stock Unit · Derivative | 14,677 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-048171 · doc4.xml · derivative · entry 6 Harbaugh Matthew K · CIK 0001578368 · EVP and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 14,677 shares Expires not disclosed F2 · derivative.exercise_price: Represented a contingent right to receive one share of the Issuer's common stock upon vesting. F4 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each performance restricted stock unit award was converted into a Globus restricted stock unit award, with the number of shares of Globus Class A Common Stock subject to such assumed award determined based on the Exchange Ratio and with applicable performance conditions deemed to be achieved at 100% of the target performance level. Each converted Globus restricted stock unit award is subject to the same terms and conditions (including service-based vesting conditions but excluding performance-based vesting conditions) as applied to the corresponding Issuer performance restricted stock unit award subject to such award as of immediately prior to the Effective Time F4 · derivative.expiration_date: Pursuant to the Merger Agreement, at the Effective Time, each performance restricted stock unit award was converted into a Globus restricted stock unit award, with the number of shares of Globus Class A Common Stock subject to such assumed award determined based on the Exchange Ratio and with applicable performance conditions deemed to be achieved at 100% of the target performance level. Each converted Globus restricted stock unit award is subject to the same terms and conditions (including service-based vesting conditions but excluding performance-based vesting conditions) as applied to the corresponding Issuer performance restricted stock unit award subject to such award as of immediately prior to the Effective Time Read SEC document |
| September 01, 2023 Filed Sep 5, 2023 16:34 UTC | NUVASIVE INC NUVA · Entity 110002 | Disposition to issuerPerformance Restricted Stock Unit · Derivative | 13,411 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-048171 · doc4.xml · derivative · entry 5 Harbaugh Matthew K · CIK 0001578368 · EVP and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 13,411 shares Expires not disclosed F2 · derivative.exercise_price: Represented a contingent right to receive one share of the Issuer's common stock upon vesting. F4 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each performance restricted stock unit award was converted into a Globus restricted stock unit award, with the number of shares of Globus Class A Common Stock subject to such assumed award determined based on the Exchange Ratio and with applicable performance conditions deemed to be achieved at 100% of the target performance level. Each converted Globus restricted stock unit award is subject to the same terms and conditions (including service-based vesting conditions but excluding performance-based vesting conditions) as applied to the corresponding Issuer performance restricted stock unit award subject to such award as of immediately prior to the Effective Time F4 · derivative.expiration_date: Pursuant to the Merger Agreement, at the Effective Time, each performance restricted stock unit award was converted into a Globus restricted stock unit award, with the number of shares of Globus Class A Common Stock subject to such assumed award determined based on the Exchange Ratio and with applicable performance conditions deemed to be achieved at 100% of the target performance level. Each converted Globus restricted stock unit award is subject to the same terms and conditions (including service-based vesting conditions but excluding performance-based vesting conditions) as applied to the corresponding Issuer performance restricted stock unit award subject to such award as of immediately prior to the Effective Time Read SEC document |
| September 01, 2023 Filed Sep 5, 2023 16:34 UTC | NUVASIVE INC NUVA · Entity 110002 | Disposition to issuerRestricted Stock Unit · Derivative | 37,498 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-048171 · doc4.xml · derivative · entry 4 Harbaugh Matthew K · CIK 0001578368 · EVP and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 37,498 shares Expires not disclosed F2 · derivative.exercise_price: Represented a contingent right to receive one share of the Issuer's common stock upon vesting. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit award was converted into a Globus restricted stock unit award, with the number of shares of Globus Class A Common Stock subject to such assumed award determined based on the Exchange Ratio. Each converted Globus restricted stock unit award is subject to the same terms and conditions (including service-based vesting conditions) as applied to the corresponding Issuer restricted stock unit award as of immediately prior to the Effective Time. F3 · derivative.expiration_date: Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit award was converted into a Globus restricted stock unit award, with the number of shares of Globus Class A Common Stock subject to such assumed award determined based on the Exchange Ratio. Each converted Globus restricted stock unit award is subject to the same terms and conditions (including service-based vesting conditions) as applied to the corresponding Issuer restricted stock unit award as of immediately prior to the Effective Time. Read SEC document |
| September 01, 2023 Filed Sep 5, 2023 16:34 UTC | NUVASIVE INC NUVA · Entity 110002 | Disposition to issuerRestricted Stock Unit · Derivative | 14,677 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-048171 · doc4.xml · derivative · entry 3 Harbaugh Matthew K · CIK 0001578368 · EVP and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 14,677 shares Expires not disclosed F2 · derivative.exercise_price: Represented a contingent right to receive one share of the Issuer's common stock upon vesting. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit award was converted into a Globus restricted stock unit award, with the number of shares of Globus Class A Common Stock subject to such assumed award determined based on the Exchange Ratio. Each converted Globus restricted stock unit award is subject to the same terms and conditions (including service-based vesting conditions) as applied to the corresponding Issuer restricted stock unit award as of immediately prior to the Effective Time. F3 · derivative.expiration_date: Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit award was converted into a Globus restricted stock unit award, with the number of shares of Globus Class A Common Stock subject to such assumed award determined based on the Exchange Ratio. Each converted Globus restricted stock unit award is subject to the same terms and conditions (including service-based vesting conditions) as applied to the corresponding Issuer restricted stock unit award as of immediately prior to the Effective Time. Read SEC document |
| September 01, 2023 Filed Sep 5, 2023 16:34 UTC | NUVASIVE INC NUVA · Entity 110002 | Disposition to issuerRestricted Stock Unit · Derivative | 13,411 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-048171 · doc4.xml · derivative · entry 2 Harbaugh Matthew K · CIK 0001578368 · EVP and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 13,411 shares Expires not disclosed F2 · derivative.exercise_price: Represented a contingent right to receive one share of the Issuer's common stock upon vesting. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit award was converted into a Globus restricted stock unit award, with the number of shares of Globus Class A Common Stock subject to such assumed award determined based on the Exchange Ratio. Each converted Globus restricted stock unit award is subject to the same terms and conditions (including service-based vesting conditions) as applied to the corresponding Issuer restricted stock unit award as of immediately prior to the Effective Time. F3 · derivative.expiration_date: Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit award was converted into a Globus restricted stock unit award, with the number of shares of Globus Class A Common Stock subject to such assumed award determined based on the Exchange Ratio. Each converted Globus restricted stock unit award is subject to the same terms and conditions (including service-based vesting conditions) as applied to the corresponding Issuer restricted stock unit award as of immediately prior to the Effective Time. Read SEC document |
| September 01, 2023 Filed Sep 5, 2023 16:34 UTC | NUVASIVE INC NUVA · Entity 110002 | Disposition to issuerCommon Stock, par value $0.001 per share | 11,081 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-048171 · doc4.xml · nonDerivative · entry 1 Harbaugh Matthew K · CIK 0001578368 · EVP and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · price: Pursuant to the Agreement and Plan of Merger, dated as of February 8, 2023 (the "Merger Agreement"), by and among the Issuer, Globus Medical, Inc. ("Globus") and Zebra Merger Sub, Inc. ("Merger Sub"), Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Globus. At the effective time of the merger (the "Effective Time"), each share of the Issuer's common stock issued and outstanding immediately prior to the Effective Time (other than certain excluded shares) was cancelled and converted into the right to receive 0.75 shares of Class A common stock of Globus ("Globus Class A Common Stock"), par value $0.001 per share (the "Exchange Ratio" and such shares, the "Merger Consideration"), and cash in lieu of fractional shares. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 17:47 UTC | NUVASIVE INC NUVA · Entity 110002 | GrantRSUs · Derivative | 37,498 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-015847 · doc4.xml · derivative · entry 4 Harbaugh Matthew K · CIK 0001578368 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,498 Underlying: Common Stock · 37,498 shares Expires not disclosed F3 · security: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's common stock upon vesting. F5 · derivative.exercise_date: This RSU award was granted to the Reporting Person on March 1, 2023. In accordance with the terms of the RSU award, the award will vest in full on March 1, 2026. F5 · derivative.expiration_date: This RSU award was granted to the Reporting Person on March 1, 2023. In accordance with the terms of the RSU award, the award will vest in full on March 1, 2026. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 17:47 UTC | NUVASIVE INC NUVA · Entity 110002 | Exercise / conversionRSUs · Derivative | 12,190 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-015847 · doc4.xml · derivative · entry 3 Harbaugh Matthew K · CIK 0001578368 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,190 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's common stock upon vesting. F4 · derivative.exercise_date: This RSU award was granted to the Reporting Person on March 2, 2020. In accordance with the terms of the RSU award, the award vested as to 12,190 shares on March 1, 2023. F4 · derivative.expiration_date: This RSU award was granted to the Reporting Person on March 2, 2020. In accordance with the terms of the RSU award, the award vested as to 12,190 shares on March 1, 2023. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 17:47 UTC | NUVASIVE INC NUVA · Entity 110002 | Tax withholdingCommon Stock | 3,526 | $42.67 | $150,454.42 |
DisclosureSEC source: 0001209191-23-015847 · doc4.xml · nonDerivative · entry 2 Harbaugh Matthew K · CIK 0001578368 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,522 F2 · shares: Shares withheld by the Issuer to satisfy tax withholding obligations. F1 · balance_after: Shares directly held by the Reporting Person. The Reporting Person also holds conditional rights to receive shares pursuant to previously disclosed Issuer equity awards. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 17:47 UTC | NUVASIVE INC NUVA · Entity 110002 | Exercise / conversionCommon Stock | 12,190 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-015847 · doc4.xml · nonDerivative · entry 1 Harbaugh Matthew K · CIK 0001578368 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,048 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Shares directly held by the Reporting Person. The Reporting Person also holds conditional rights to receive shares pursuant to previously disclosed Issuer equity awards. Read SEC document |
| January 01, 2023 Filed Jan 3, 2023 17:54 UTC | NUVASIVE INC NUVA · Entity 110002 | Exercise / conversionRSUs · Derivative | 1,286 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-000364 · doc4.xml · derivative · entry 3 Harbaugh Matthew K · CIK 0001578368 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,286 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's common stock upon vesting. F4 · derivative.exercise_date: This RSU award was granted to the Reporting Person on January 2, 2020. In accordance with the terms of the RSU award, the award vested as to 1,286 shares on January 1, 2023. F4 · derivative.expiration_date: This RSU award was granted to the Reporting Person on January 2, 2020. In accordance with the terms of the RSU award, the award vested as to 1,286 shares on January 1, 2023. Read SEC document |
| January 01, 2023 Filed Jan 3, 2023 17:54 UTC | NUVASIVE INC NUVA · Entity 110002 | Tax withholdingCommon Stock | 440 | $41.24 | $18,145.60 |
DisclosureSEC source: 0001209191-23-000364 · doc4.xml · nonDerivative · entry 2 Harbaugh Matthew K · CIK 0001578368 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,858 F2 · shares: Shares withheld by the Issuer to satisfy tax withholding obligations. F1 · balance_after: Shares directly held by the Reporting Person. The Reporting Person also holds conditional rights to receive shares pursuant to previously disclosed Issuer equity awards. Amount includes 555 shares acquired under the Issuer's employee stock purchase plan in April 2021 and 457 shares acquired under the Issuer's employee stock purchase plan in April 2022. Read SEC document |
| January 01, 2023 Filed Jan 3, 2023 17:54 UTC | NUVASIVE INC NUVA · Entity 110002 | Exercise / conversionCommon Stock | 1,286 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-000364 · doc4.xml · nonDerivative · entry 1 Harbaugh Matthew K · CIK 0001578368 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,298 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Shares directly held by the Reporting Person. The Reporting Person also holds conditional rights to receive shares pursuant to previously disclosed Issuer equity awards. Amount includes 555 shares acquired under the Issuer's employee stock purchase plan in April 2021 and 457 shares acquired under the Issuer's employee stock purchase plan in April 2022. Read SEC document |
| March 01, 2022 Filed Mar 3, 2022 17:50 UTC | NUVASIVE INC NUVA · Entity 110002 | GrantRSUs · Derivative | 14,677 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-015762 · doc4.xml · derivative · entry 1 Harbaugh Matthew K · CIK 0001578368 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,677 Underlying: Common Stock · 14,677 shares Expires not disclosed F1 · security: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's common stock upon vesting. F2 · derivative.exercise_date: This RSU award was granted to the Reporting Person on March 1, 2022. In accordance with the terms of the RSU award, the award will vest in full on March 1, 2025. F2 · derivative.expiration_date: This RSU award was granted to the Reporting Person on March 1, 2022. In accordance with the terms of the RSU award, the award will vest in full on March 1, 2025. Read SEC document |
| March 01, 2021 Filed Mar 3, 2021 17:49 UTC | NUVASIVE INC NUVA · Entity 110002 | GrantRSUs · Derivative | 13,411 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-017144 · doc4.xml · derivative · entry 1 Harbaugh Matthew K · CIK 0001578368 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,411 Underlying: Common Stock · 13,411 shares Expires not disclosed F1 · security: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's common stock upon vesting. F2 · derivative.exercise_date: This RSU award was granted to the Reporting Person on March 1, 2021. In accordance with the terms of the RSU award, the award will vest in full on March 1, 2024. F2 · derivative.expiration_date: This RSU award was granted to the Reporting Person on March 1, 2021. In accordance with the terms of the RSU award, the award will vest in full on March 1, 2024. Read SEC document |
| March 02, 2020 Filed Mar 3, 2020 17:50 UTC | NUVASIVE INC NUVA · Entity 110002 | GrantRSUs · Derivative | 12,190 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-015520 · doc4.xml · derivative · entry 1 Harbaugh Matthew K · CIK 0001578368 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,190 Underlying: Common Stock · 12,190 shares Expires not disclosed F1 · security: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's common stock upon vesting. F2 · derivative.exercise_date: This RSU award was granted to the Reporting Person on March 2, 2020. In accordance with the terms of the RSU award, the award will vest in full on March 1, 2023. F2 · derivative.expiration_date: This RSU award was granted to the Reporting Person on March 2, 2020. In accordance with the terms of the RSU award, the award will vest in full on March 1, 2023. Read SEC document |
| January 02, 2020 Filed Jan 3, 2020 17:49 UTC | NUVASIVE INC NUVA · Entity 110002 | GrantRSUs · Derivative | 1,286 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-001324 · doc4.xml · derivative · entry 1 Harbaugh Matthew K · CIK 0001578368 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,286 Underlying: Common Stock · 1,286 shares Expires not disclosed F1 · security: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's common stock upon vesting. F2 · derivative.exercise_date: This RSU award was granted to the Reporting Person on January 2, 2020. In accordance with the terms of the RSU award, the award will vest as to 1,286 shares on January 1, 2023. F2 · derivative.expiration_date: This RSU award was granted to the Reporting Person on January 2, 2020. In accordance with the terms of the RSU award, the award will vest as to 1,286 shares on January 1, 2023. Read SEC document |
| April 02, 2019 Filed Apr 3, 2019 21:27 UTC | Keenova Therapeutics plc MNK · Entity 28960 | Tax withholdingOrdinary Shares | 2,533 | $22.80 | $57,752.40 |
DisclosureSEC source: 0000950138-19-000215 · edgar.xml · nonDerivative · entry 1 Harbaugh Matthew K · CIK 0001578368 · EVP & President, Spec Gen 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,115 Read SEC document |
| January 04, 2019 Filed Jan 7, 2019 22:47 UTC | Keenova Therapeutics plc MNK · Entity 28960 | Tax withholdingOrdinary Shares | 656 | $17.21 | $11,289.76 |
DisclosureSEC source: 0000950138-19-000017 · edgar.xml · nonDerivative · entry 2 Harbaugh Matthew K · CIK 0001578368 · President, Spec Gen 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,648 Read SEC document |
| January 03, 2019 Filed Jan 7, 2019 22:47 UTC | Keenova Therapeutics plc MNK · Entity 28960 | Tax withholdingOrdinary Shares | 1,180 | $16.14 | $19,045.20 |
DisclosureSEC source: 0000950138-19-000017 · edgar.xml · nonDerivative · entry 1 Harbaugh Matthew K · CIK 0001578368 · President, Spec Gen 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,304 Read SEC document |
| January 02, 2019 Filed Jan 4, 2019 22:45 UTC | Keenova Therapeutics plc MNK · Entity 28960 | Tax withholdingOrdinary Shares | 341 | $16.59 | $5,657.19 |
DisclosureSEC source: 0000950138-19-000003 · edgar.xml · nonDerivative · entry 1 Harbaugh Matthew K · CIK 0001578368 · President, Spec Gen 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,484 F1 · balance_after: Includes 704 shares acquired between June 30, 2018 and December 31, 2018 under the Mallinckrodt employee stock purchase plan. Read SEC document |
| April 02, 2018 Filed Apr 4, 2018 22:05 UTC | Keenova Therapeutics plc MNK · Entity 28960 | GrantEmployee Share Options (Right to Buy) · Derivative | 177,849 | $0.00 Strike: $13.80 | $0.00 |
DisclosureSEC source: 0000950138-18-000309 · edgar.xml · derivative · entry 2 Harbaugh Matthew K · CIK 0001578368 · Exec. VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 177,849 Underlying: Ordinary Shares · 177,849 shares Expires 2028-04-02 F3 · derivative.exercise_date: The options vest in four equal annual installments beginning April 2, 2019. Read SEC document |
| April 02, 2018 Filed Apr 4, 2018 22:05 UTC | Keenova Therapeutics plc MNK · Entity 28960 | GrantOrdinary Shares | 34,058 | $0.00 | $0.00 |
DisclosureSEC source: 0000950138-18-000309 · edgar.xml · nonDerivative · entry 1 Harbaugh Matthew K · CIK 0001578368 · Exec. VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,121 F1 · shares: Represents restricted stock units that vest in four equal annual installments beginning April 2, 2019. F2 · balance_after: Includes 623 shares acquired on March 31, 2018 under the Mallinckrodt employee stock purchase plan. Read SEC document |
| January 04, 2018 Filed Jan 6, 2018 00:16 UTC | Keenova Therapeutics plc MNK · Entity 28960 | Tax withholdingOrdinary Shares | 838 | $23.40 | $19,609.20 |
DisclosureSEC source: 0000950138-18-000035 · edgar.xml · nonDerivative · entry 2 Harbaugh Matthew K · CIK 0001578368 · Exec. VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,440 Read SEC document |
| January 03, 2018 Filed Jan 6, 2018 00:16 UTC | Keenova Therapeutics plc MNK · Entity 28960 | Tax withholdingOrdinary Shares | 1,508 | $23.51 | $35,453.08 |
DisclosureSEC source: 0000950138-18-000035 · edgar.xml · nonDerivative · entry 1 Harbaugh Matthew K · CIK 0001578368 · Exec. VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,278 Read SEC document |
| January 02, 2018 Filed Jan 5, 2018 00:21 UTC | Keenova Therapeutics plc MNK · Entity 28960 | Tax withholdingOrdinary Shares | 1,610 | $23.52 | $37,867.20 |
DisclosureSEC source: 0000950138-18-000028 · edgar.xml · nonDerivative · entry 2 Harbaugh Matthew K · CIK 0001578368 · Exec. VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,786 Read SEC document |
| January 02, 2018 Filed Jan 5, 2018 00:21 UTC | Keenova Therapeutics plc MNK · Entity 28960 | GrantOrdinary Shares | 2,404 | $0.00 | $0.00 |
DisclosureSEC source: 0000950138-18-000028 · edgar.xml · nonDerivative · entry 1 Harbaugh Matthew K · CIK 0001578368 · Exec. VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,396 F1 · shares: Vesting of performance share award granted on January 2, 2015. F2 · balance_after: Includes 324 shares acquired between June 30, 2017 and September 30, 2017 under the Mallinckrodt employee stock purchase plan. Read SEC document |
| July 01, 2017 Filed Jul 5, 2017 20:19 UTC | Keenova Therapeutics plc MNK · Entity 28960 | Tax withholdingOrdinary Shares | 1,620 | $44.81 | $72,592.20 |
DisclosureSEC source: 0000950138-17-000518 · edgar.xml · nonDerivative · entry 1 Harbaugh Matthew K · CIK 0001578368 · Exec. VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,668 F1 · balance_after: Includes 203 shares acquired on March 31, 2017 under the Mallinckrodt employee stock purchase plan. Read SEC document |
| March 10, 2017 Filed Mar 14, 2017 12:40 UTC | Keenova Therapeutics plc MNK · Entity 28960 | PurchaseOrdinary Shares | 600 | $49.19 | $29,514.00 |
DisclosureSEC source: 0000950138-17-000319 · edgar.xml · nonDerivative · entry 1 Harbaugh Matthew K · CIK 0001578368 · Exec. VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,085 F1 · price: The price represents a weighted average. The shares were purchased in multiple transactions at prices ranging from $49.18 to $49.22, inclusive. Mr. Harbaugh will provide, upon request of the SEC staff, Mallinckrodt plc or a shareholder of Mallinckrodt plc complete information regarding the number of shares sold at each price within the range. F2 · balance_after: Includes 156 shares acquired on December 31, 2016, under the Mallinckrodt employee stock purchase plan. Read SEC document |
| January 04, 2017 Filed Jan 6, 2017 23:12 UTC | Keenova Therapeutics plc MNK · Entity 28960 | Tax withholdingOrdinary Shares | 724 | $53.19 | $38,509.56 |
DisclosureSEC source: 0000950138-17-000051 · edgar.xml · nonDerivative · entry 1 Harbaugh Matthew K · CIK 0001578368 · Exec. VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,329 Read SEC document |
| January 03, 2017 Filed Jan 5, 2017 01:42 UTC | Keenova Therapeutics plc MNK · Entity 28960 | GrantEmployee Share Options (Right to Buy) · Derivative | 63,397 | $0.00 Strike: $51.73 | $0.00 |
DisclosureSEC source: 0000950138-17-000014 · edgar.xml · derivative · entry 6 Harbaugh Matthew K · CIK 0001578368 · Exec. VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,397 Underlying: Ordinary Shares · 63,397 shares Expires 2027-01-03 F5 · derivative.exercise_date: The options vest in their entirety on January 3, 2021. Read SEC document |
| January 03, 2017 Filed Jan 5, 2017 01:42 UTC | Keenova Therapeutics plc MNK · Entity 28960 | GrantEmployee Share Options (Right to Buy) · Derivative | 74,675 | $0.00 Strike: $51.73 | $0.00 |
DisclosureSEC source: 0000950138-17-000014 · edgar.xml · derivative · entry 5 Harbaugh Matthew K · CIK 0001578368 · Exec. VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,675 Underlying: Ordinary Shares · 74,675 shares Expires 2027-01-03 F4 · derivative.exercise_date: The options vest in four equal annual installments beginning January 3, 2018. Read SEC document |
| January 03, 2017 Filed Jan 5, 2017 01:42 UTC | Keenova Therapeutics plc MNK · Entity 28960 | GrantOrdinary Shares | 1,718 | $0.00 | $0.00 |
DisclosureSEC source: 0000950138-17-000014 · edgar.xml · nonDerivative · entry 4 Harbaugh Matthew K · CIK 0001578368 · Exec. VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,053 F3 · shares: Represents restricted stock units that vest in three equal annual installments beginning January 3, 2018. Read SEC document |
| January 03, 2017 Filed Jan 5, 2017 01:42 UTC | Keenova Therapeutics plc MNK · Entity 28960 | GrantOrdinary Shares | 13,293 | $0.00 | $0.00 |
DisclosureSEC source: 0000950138-17-000014 · edgar.xml · nonDerivative · entry 3 Harbaugh Matthew K · CIK 0001578368 · Exec. VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,335 F2 · shares: Represents restricted stock units that vest in four equal annual installments beginning January 3, 2018. Read SEC document |
| January 02, 2017 Filed Jan 5, 2017 01:42 UTC | Keenova Therapeutics plc MNK · Entity 28960 | Tax withholdingOrdinary Shares | 4,334 | $49.82 | $215,919.88 |
DisclosureSEC source: 0000950138-17-000014 · edgar.xml · nonDerivative · entry 2 Harbaugh Matthew K · CIK 0001578368 · Exec. VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,042 Read SEC document |
| January 02, 2017 Filed Jan 5, 2017 01:42 UTC | Keenova Therapeutics plc MNK · Entity 28960 | GrantOrdinary Shares | 10,864 | $0.00 | $0.00 |
DisclosureSEC source: 0000950138-17-000014 · edgar.xml · nonDerivative · entry 1 Harbaugh Matthew K · CIK 0001578368 · Exec. VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,376 F1 · shares: Vesting of performance share award granted on January 2, 2014. Read SEC document |
| December 03, 2016 Filed Dec 6, 2016 13:22 UTC | Keenova Therapeutics plc MNK · Entity 28960 | Tax withholdingOrdinary Shares | 297 | $53.61 | $15,922.17 |
DisclosureSEC source: 0000950138-16-001491 · edgar.xml · nonDerivative · entry 1 Harbaugh Matthew K · CIK 0001578368 · Exec. VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,512 F1 · balance_after: Includes 191 shares acquired between July 5, 2016 and September 30, 2016, under the Mallinckrodt employee stock purchase plan. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.